Status:
RECRUITING
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
Lead Sponsor:
Zhejiang Provincial People's Hospital
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-s...
Detailed Description
Ovarian cancer is a common gynecological malignancy with the highest mortality rate among gynecological cancers. The poor prognosis and low survival rate in advanced-stage patients primarily contribut...
Eligibility Criteria
Inclusion
- Patients voluntarily participate in the study, sign informed consent forms, and have good compliance.
- After platinum based chemotherapy at Zhejiang Provincial People's Hospital, the efficacy evaluation showed that ovarian cancer patients who achieved disease stability (SD) or disease progression (PD) twice were treated with Fasudil in combination with the original chemotherapy regimen, and were confirmed to have the A/A genotype through genetic testing.
Exclusion
- Accompanied by hypotension 2. Bleeding like cerebral hemorrhage 3. Patients with abnormal liver function
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06890858
Start Date
April 1 2025
End Date
January 1 2028
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China